Mr. Speaker, I add my voice to that of other members to congratulate all the parliamentarians in this House who have worked on making this bill the best and the most perfect bill possible.
Admittedly, this is a highly humanitarian bill. In the past, our examination of drug costs and issues related to research and development has tended to cause division between the parties.
I believe that the current Minister of Human Resources and Skills Development was the Minister of Industry at the time when this bill was referred to the committee. The committee achieved a perfect consensus, which should also be reflected in the allocation for the Summer Career Placements Program this year. But that is for another debate. Without digressing, I would like to plead in favour of the status quo, if the minister gets my drift.
That having been said, I have three short questions for my hon. colleague. First, could he remind the House of the degree of cooperation that was anticipated in connection with this GMO issue? I know that there were expectations concerning the bill in that respect. Second, could he remind us of the difference between compulsory licensing and the current system? Third, could he remind us of the importance of schedule I, which lists the countries which will be allowed to bid and to which the shipping of medicine will be allowed? I think it would be helpful, for the benefit of our fellow citizens, if he could read this list.